The subject of the order is the purchase and successive delivery of reimbursed drugs covered by the drug program:

1) treatment of chronic hepatitis C with noninterferon therapy;

2) treatment of multiple sclerosis.

Interferonum beta-1a solutions to shake 0.03 mg / 0.5 ml

Glatirameri acetas solution for injection in ampoules 0.04 g / ml

Interferon beta-1b 0.3 mg - 9.6 million IU + solution for solution to shake 0.25 mg / ml

Interferon beta-1a x4 cartridges inj. Sc 132 mcg (36 million) / 1.5 ml (24 M IU)

Teriflunomidum film-coated tablets 0.014 g

Dimethyl fumarate capsule hard 120 mg

Dimethyl fumarate capsule hard 240 mg

Peginterferon beta-1a solution to shake 125 mcg

Peginterferon beta-1a solution for injection 63 mcg + 94 mcg

Elbasvir, Grazoprevir film-coated tablets 0.05 g + 0.1g

Ribavirinum hard capsules 0.2 g

Glecaprevirum, Pibrentasvirum film-coated tablets 0.1 g + 0.04 g

Sofosbuvirum, Velpatasvirum film-coated tablets 0.4 g + 0.1 g